Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 372Neoplasms 325Neoplasm Metastasis 288Leukemia, Myeloid, Acute 280Breast Neoplasms 272Colorectal Neoplasms 239Melanoma 193Ovarian Neoplasms 190Recurrence 184Multiple Myeloma 178Prostatic Neoplasms 158Lung Neoplasms 158Pancreatic Neoplasms 151Squamous Cell Carcinoma of Head and Neck 150Lymphoma, Non-Hodgkin 147Glioblastoma 146Triple Negative Breast Neoplasms 119Myelodysplastic Syndromes 115Carcinoma, Renal Cell 111Stomach Neoplasms 110Glioma 109Brain Neoplasms 105Advanced Solid Tumors 105Precursor Cell Lymphoblastic Leukemia-Lymphoma 104Lymphoma, Large B-Cell, Diffuse 102Lymphoma 102Lymphoma, B-Cell 97Carcinoma, Hepatocellular 95Lymphoma, Follicular 92Endometrial Neoplasms 92

Interventions

darolutamide 1Rifampin 1Itraconazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Refractory or Relapsed Solid Tumors × 1 year × Clear all
NCT07620041 2026-06-02

QLC5508 in Advanced Solid Tumors:: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction

Qilu Pharmaceutical Co., Ltd.

Phase 1 Not yet recruiting
48 enrolled
Other solid neoplasm

Refractory or Relapsed Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡